Wendell D. Wierenga
Independent DirectorDr. Wendell D. Wierenga, Ph.D., had been an Independent Chairman of Crinetics Pharmaceuticals, Inc since October 2015 until September 1, 2026. Dr. Wierenga served as an Executive Vice President of Research & Development at Santarus, Inc., from June 2011 to January 2, 2014 it was acquired by Salix Pharmaceuticals, Ltd. in January 2014. Dr. Wierenga served as a Consultant of Neurocrine Biosciences Inc., from December 21, 2006 to 2008. He served as Executive Vice President of Research and Development of Neurocrine Biosciences Inc., from September 1, 2003 to December 21, 2006, where he managed a portfolio of six clinical programs including five INDs and two NDAs. He has experience in matters relating to pharmaceutical drug discovery and development in a wide range of therapeutic areas and an extensive background as a public company executive and board member in the pharmaceutical and biotechnology industries. He served as an Executive Vice President of Research & Development at Ambit Biosciences Corporation from July 2004 to May 2011. He served as Executive Vice President, Research and Development at both Ambit Biosciences and Neurocrine Biosciences. He served as Chief Executive Officer of Syrrx, Inc., since 2005. Dr. Wierenga served as the Chief Executive Officer of Takeda California, Inc. (also known as Syrrx, Inc. and Takeda San Diego, Inc.) from September 2000 to August 2003. He served as Director at Seelos Therapeutics, Inc. until January 24, 2019. He served as Vice President of Med-Tech Ventures, Inc. from 1992 to 2000. From 1990 to 2000, he served as Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert (now Pfizer, Inc.). He served as Senior Vice President of Research of Parke-Davis from 1990 to February 1999. At Parke-Davis, he was responsible for worldwide drug development, including toxicology, pharmacokinetics/drug metabolism, chemical development, pharmaceutics, clinical supplies, information systems and technology acquisition. He served as WW Head of R&D/Senior Vice President, Preclinical Research, Development and Technologies for the Pharmaceutical Research Division of Parke-Davis. He was responsible for the successful integration of Agouron and Parke-Davis R&D and for the management of 25 biotechnology corporate partnerships exceeding 750 million in pre-commercialization value. Dr. Wierenga served as an Executive Director of Discovery Research of Upjohn Pharmaceuticals, where he held a succession of research and development positions from 1974 to 1990. He served as Vice Chairman at Ambit Biosciences Corporation. He was an Independent Director of SRI International, Inc. since January 2014. He has been an Independent Director of Cytokinetics, Incorporated since February 10, 2011. He has been an Independent Director of Dermata Therapeutics, Inc. since September 20, 2016. He serves on the scientific advisory board for Ferring Pharmaceuticals Research Institute and Concert Pharmaceuticals. He has been a Member of Life Sciences Strategy Advisory Board at Agilent Technologies, Inc. since February 4, 2003. He was Director of Patara Pharma, Incorporated from 2015 to November 2018. He had been a Member of Therapeutic Advisory Board at aTyr Pharma Inc. since March 1, 2011. He serves as a Director at Crinetics Pharmaceuticals, Inc since 2014. Dr. Wierenga has been a Director of Apricus Biosciences, Inc. since March 10, 2014. Dr. Wierenga served as Independent Director of Ocera Therapeutics, Inc. since December 19, 2013 until December 11, 2017 and it was acquired by Mallinckrodt in 2017. He served as a Member of Product Advisory Board at Concert Pharmaceuticals, Inc. and was its Director since March 14, 2014 until June 2019. He served as a Director of Takeda California, Inc. and Onyx Pharmaceuticals, Inc. since December 1996, it was acquired by Amgen in 2013. He served as a Director of Anacor Pharmaceuticals, Inc. from September 2014 to June 24, 2016 it was acquired by Pfizer in 2016, XenoPort, Inc. from 2000 to July 5, 2016 it was acquired by Arbor Pharmaceuticals in 2016. He served as a Director of Vermillion, Inc. from 2002 to June 7, 2006 and Aurora Biosciences Corporation since October 2000. He served on the board of Directors of GenVec, Inc. and Ambit Biosciences Corporation. Dr. Wierenga serves on several scientific advisory boards, including Sojournix, Inc and Ocelot Bio. He has been an Adjunct Professor in the Department of Chemistry at the University of Michigan since 1997. He led/participated in the research and development of more than 60 Investigational New Drugs (INDs), over 10 New Drug Applications (NDAs) and over 10 marketed products, including Lipitor(R) and Neurontin(R). He has over 190 publications and presentations. Dr. Wierenga has published more than 55 original articles, 100 abstracts and invited lectures and is a primary inventor on 30 patents. He holds a B.A. in Chemistry from Hope College in Holland, Michigan and Ph.D. in Chemistry from Stanford University and an American Cancer Society Postdoctoral Fellowship at Stanford.
公司职务
- 公司名称Dermata Therapeutics, Inc.股票代码DRMA职务Independent Director共事同僚
- GTGerald T. ProehlFounder, President, CEO & Chairman
- DFDavid F. HaleCo-Founder & Lead Independent Director
- KKKyri K. Van HooseSenior VP & CFO
- CJChristopher J. NardoSenior VP & Chief Development Officer
- SPSean ProehlAssociate General Counsel
- KDKathleen D. ScottIndependent Director
- ASAndrew Seth SandlerIndependent Director
